Israeli biopharma firm Omnix Medical nets $25m series C
- ByStartupStory | November 2, 2025
Israeli biopharma firm Omnix Medical has announced a successful €25 million ($25 million) Series C funding round, led by Israeli investment firm Harel Insurance & Finance, along with the European Innovation Council (EIC) Fund. This significant infusion of capital aims to accelerate the development and clinical testing of Omnix’s innovative anti-infective therapies designed to combat multidrug-resistant bacterial infections.
Founded in 2015, Omnix specializes in engineered antimicrobial peptides (AMPs), focusing on rapidly destroying bacterial membranes to treat life-threatening infections, including those caused by resistant Gram-negative bacteria such as Acinetobacter baumannii. The company’s lead compound, OMN6, has already received Fast-Track and QIDP (Qualified Infectious Disease Product) designations from the U.S. Food and Drug Administration (FDA), reinforcing its potential as a groundbreaking solution.
The fresh funds will be utilized to complete Phase II proof-of-concept clinical trials for OMN6, support regulatory activities, scale manufacturing, and advance a broader pipeline of antimicrobial peptides. The investment underscores the urgent global need for novel, resistance-proof antibiotics in the face of rising antimicrobial resistance (AMR).
Tomer Goldberg, Managing Director at Harel Insurance & Finance, highlighted the societal importance of combating resistant infections, affirming Harel’s commitment to supporting biotech innovation. Dr. Moshik Cohen-Kutner, CEO of Omnix, expressed confidence that the funding will enable the company to demonstrate OMN6’s potential to revolutionize treatment for multidrug-resistant infections, harnessing its unique mechanism of membrane destruction to minimize resistance development.
Supported by grants from the Israeli Innovation Authority and the European Union’s Horizon 2020 program, Omnix’s technology leverages high-selectivity engineered peptides that rapidly target bacterial membranes, providing an effective and swift therapeutic option with a reduced likelihood of resistance emergence.
In summary, Omnix’s €25 million Series C funding marks a crucial step forward in its mission to develop next-generation antibiotics, addressing a critical unmet need in global healthcare. With robust financial backing and promising clinical prospects, Omnix is well on its way to transforming the landscape of infectious disease treatment and combating the global antimicrobial resistance crisis.
Follow Startup Story
Related Posts
